Regeneron Pharmaceuticals Newsroom

Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner

Zacks 20:50

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients

Benzinga02:05

Regeneron Gains 13.5% Year to Date: How to Play the Stock?

Zacks Oct 9 02:30

Pharmaceutical company warns: if muscle loss issue is not addressed, 'miracle weight-loss drugs' may do more harm than good.

①USA pharmaceutical company Regeneron stated that current GLP-1 weight loss drugs can lead to rapid muscle loss, and the company is developing a weight loss drug that can overcome this flaw; ② Regeneron warned that if the muscle loss issue is not resolved, GLP-1 weight loss drugs may do more harm than good.

cls.cnOct 7 22:42

Regeneron Sees $56M Pretax Charge Hitting 3Q Earnings

WSJOct 7 19:54

Regeneron Sees IPR&D Impact of About $0.43/share on Q3 Income

Seeking AlphaOct 7 19:21

Express News | Regeneron Pharmaceuticals - Expects Q3 Results Will Include Acquired Ipr&D Charge of Sbout $56 Mln on Pre-Tax Basis

BreakingsOct 7 19:01

Regeneron Co-founder Warns of Harms From Weight-loss Drugs: FT

Seeking AlphaOct 6 22:29

Regeneron Pharma Is Maintained at Outperform by RBC Capital

Dow JonesOct 4 23:21 · Ratings

Regeneron Pharmaceuticals Analyst Ratings

BenzingaOct 4 23:08 · Ratings

RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating

MT NewswiresOct 4 19:06 · Ratings

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing

MT NewswiresOct 4 04:12

Market Whales and Their Recent Bets on REGN Options

BenzingaOct 4 02:34

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest

BenzingaOct 4 01:45

Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?

Simply Wall StOct 1 19:38

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today

BenzingaSep 30 23:00

Erste Group Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating

Futu NewsSep 30 20:34 · Ratings

Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,220

Futu NewsSep 30 15:32 · Ratings

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?

BenzingaSep 30 01:25

Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales

Seeking AlphaSep 30 00:12